0
0 item
View CartYour cart is empty
Innotox cosmetic treatments have become more popular in recent years, similar to all Korean Botox injections. However, as its FDA approval is currently absent, some people are wondering whether this botulinum toxin formulation is safe enough to try. In today’s article, we are going to explain Innotox safety regulations, essential safety information, and other nuances your clients may find helpful. Share this blog post with those who may find it helpful before facial rejuvenation procedures.
All information in this article is provided for informational purposes only. To decide whether Innotox is the right injectable for the treatment, a consultation with an authorized medical provider is required. The procedure is gaining popularity, which is why we would like to highlight it to more people and provide a clear understanding of the product’s unique features.
Has Innotox Received Its FDA Approval in the USA?
Innotox is a liquid formulation of botulinum toxin type A developed in South Korea. It is also known among specialists as liquid botulinum toxin, which is highly beneficial because it reduces the chances of human-made errors during reconstitution. Traditional Botox requires reconstitution with sterile saline, which may get in the way of desired outcomes and patient satisfaction, as there is a possibility of dosage miscalculation, incorrect proportions, saline quality, and other aspects. Overall, the process becomes riskier if human factors are involved.
Innotox has not been approved by the Food and Drug Administration (FDA), and it is not currently under FDA review — the manufacturer has not filed the application that would begin that process. It is approved by the Korean Ministry of Food and Drug Safety (MFDS) and is widely used in Asia. Specialists choose Innotox for a range of cosmetic indications, primarily dynamic facial wrinkle reduction. The correct type of botulinum toxin injection and its frequency must be chosen by a professional based on one’s needs, which is why consultation in the doctor’s office is always an essential step.
Innotox and Botox Side by Side
The two products share an active ingredient but differ in the details that matter day to day in a clinic:
| Parameter | Innotox | Botox (onabotulinumtoxinA) |
|---|---|---|
| Form supplied | Ready-to-use liquid, no reconstitution | Freeze-dried powder, requires reconstitution with sterile saline |
| Stabiliser | No human serum albumin, no animal-derived ingredients | Contains human serum albumin |
| Storage | Refrigerated, 2–8 °C | Refrigerated, 2–8 °C |
| US regulatory status | Not FDA-approved; no application filed | FDA-approved for cosmetic and therapeutic indications |
| Approval held | Korean MFDS | FDA, EMA, MFDS and others |
“The efficacy and safety of MT10109L were comparable to those of Botox for the management of glabellar frown lines. MT10109L provides greater convenience because it does not require dilution.” — Kim et al., Plastic and Reconstructive Surgery (2015), phase III trial of the liquid formulation marketed as Innotox
Is the Procedure Complicated?
Injecting botulinum toxin requires knowledge of facial anatomy and sterile technique; self-injection raises the risk of severe adverse events. The procedure itself is similar to any other botulinum toxin product: target areas should be examined, the correct dose should be calculated, and the solution can be administered once the skin is cleaned. The administration must be performed directly into the muscle to relax facial muscles and prevent them from contracting, eliminating dynamic facial wrinkles.
The procedure is generally brief, and patients can usually resume most normal activities afterward. Results develop gradually as the treated muscles temporarily relax. Patients should receive individualized aftercare instructions and information about possible side effects before leaving the clinic.
Expected Adverse Reactions after Innotox Botulinum Toxin
Innotox contains no human serum albumin or animal-derived ingredients. The absence of complexing proteins and albumin is thought to lower the immunogenic stimulus, though direct comparative data on resistance remain limited.
The most common side effects following Innotox injections are generally mild and temporary. They may include:
- Pain or tenderness at the injection site;
- Mild swelling;
- Bruising;
- Headache;
- A feeling of heaviness in the eyelid or temporary drooping;
- Minor facial asymmetry.
Many of these reactions are caused by the injection itself rather than the botulinum toxin and usually improve within a few days to one week. Applying a cold compress may help reduce swelling, while suitable over-the-counter medication may be used to relieve pain or discomfort when appropriate.
Patients considering botulinum toxin treatments such as Innotox should understand the possible side effects before undergoing treatment. Discussing these reactions in advance helps patients make informed decisions and feel more comfortable and confident about the procedure.
“Distant Spread of Toxin Effect: Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.” — U.S. Food and Drug Administration, BOTOX Prescribing Information, boxed warning. The warning is a class effect and applies to botulinum toxin products generally, Innotox included.
Aftercare Recommendations after Aesthetic Enhancement
Most people can return to their usual activities shortly after receiving Botox injections. Although there is plenty of conflicting advice online, very little special aftercare is generally required when the treatment is performed correctly.
A few precautions may still be helpful. Remain upright for three to four hours after the injections, and avoid lying down during that time. Do not rub or massage the treated areas for approximately 12 hours, as this may affect how the product settles.
It is also advisable to avoid alcohol on the day of treatment. Medications such as aspirin, ibuprofen, and naproxen sodium may increase the likelihood of bruising, so patients should discuss their use with a qualified healthcare professional rather than stopping prescribed medication on their own.
Many post-treatment recommendations are intended to improve comfort and reduce bruising. Unwanted effects are more commonly associated with injection technique than with a patient’s normal activities after treatment.
References
Kim, J. E., Song, E. J., Choi, G. S., Lew, B. L., Sim, W. Y., & Kang, H. (2015). The Efficacy and Safety of Liquid-Type Botulinum Toxin Type A for the Management of Moderate to Severe Glabellar Frown Lines. Plastic and Reconstructive Surgery, 135(3), 732-741. https://pubmed.ncbi.nlm.nih.gov/25719692/
U.S. Food and Drug Administration. (2021). BOTOX / BOTOX Cosmetic (onabotulinumtoxinA) for injection: Full Prescribing Information. Silver Spring, MD: Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103000s5320lbl.pdf
Nigam, P. K., & Nigam, A. (2023). Botulinum Toxin. Treasure Island, FL: StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557387/
Open Medscience. Korean Botulinum Toxin Type A Products in Aesthetic Medicine: Regulatory Status, Formulations, and Clinical Evidence. https://openmedscience.com/korean-botulinum-toxin-type-a-products-in-aesthetic-medicine-regulatory-status-formulations-and-clinical-evidence/
The main difference is the form. Botox is supplied as a freeze-dried powder that must be reconstituted with sterile saline before use, while Innotox comes ready-to-use as a liquid, which removes the dilution step and the errors that can come with it. Innotox is also stabilised without human serum albumin. Storage is the same for both: refrigerated at 2–8 °C.
No. Innotox is not FDA-approved, and it is not currently under FDA review either — the manufacturer has not filed the application that would start that process, so it should not be described as pending. It holds approval from the Korean MFDS and is used widely in Asia. Purchase only from a trustworthy supplier: products obtained through unauthorised sellers may be counterfeit or improperly stored, compromising patient safety.
Innotox is generally reported to show visible effects within 2 to 3 days, while Botox typically takes 4 to 7 days. In the phase III trial comparing the two for glabellar lines, improvement rates were similar at week 4, and at week 16 the liquid formulation scored higher on maximum frown. Both products are effective, so the choice is usually made on clinical preference rather than speed alone.
Serious reactions are uncommon but possible, and the most important is distant spread of toxin effect — a class warning that applies to all botulinum toxin products. Signs include difficulty swallowing or breathing, severe allergic reactions, and muscle weakness beyond the treated area. Practitioners should screen patients carefully, keep emergency equipment available, and tell patients to seek immediate medical attention for breathing difficulty, chest tightness, significant swelling, or unusual muscle weakness.
Botox is the more established option, particularly in countries where it is formally approved: decades of clinical use, extensive safety data, standardised prescribing guidance, and approval across many cosmetic and medical indications. Innotox showed a safety profile comparable to Botox in a phase III trial for glabellar lines with no severe adverse events, but its evidence base is narrower. Note also that botulinum toxin units are product-specific and are never interchangeable between brands.
